Flow cytometry: Marginal Zone Lymphoma: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
!colspan="4" style = "font-size:110%; color: navy; text-align:center; background:#DEE0DE;"|'''Immunophenotype of MZL''' | !colspan="4" style = "font-size:110%; color: navy; text-align:center; background:#DEE0DE;"|'''Immunophenotype of MZL''' | ||
|- | |- | ||
!colspan="4" style = "font-size:90%; background:#DAE8F2"| | !colspan="4" style = "font-size:90%; background:#DAE8F2"|Major markers useful in diagnosis | ||
|- | |- | ||
|colspan="1" style = "font-size:80%; width: 4%; |'''Marker''' | |colspan="1" style = "font-size:80%; width: 4%; |'''Marker''' | ||
| Line 31: | Line 31: | ||
|colspan="1" style = "font-size:80%; width: 80%; |'''Comment''' | |colspan="1" style = "font-size:80%; width: 80%; |'''Comment''' | ||
|- | |- | ||
|colspan="1" style = "width: 4%; font-size:90%; color:black;" | | |colspan="1" style = "width: 4%; font-size:90%; color:black;" |κ/λ | ||
|colspan="1" style = "width: 8%; background:#004466;"| | |colspan="1" style = "width: 8%; background:#004466;"| | ||
|colspan="1" style = "font-size:80%; width: 8%; | | |colspan="1" style = "font-size:80%; width: 8%; | | ||
|colspan="1" style = "font-size:80%;"|Expect moderate or strong restricted κ or λ expression | |colspan="1" style = "font-size:80%;"|Expect moderate or strong restricted κ or λ expression | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" | | |colspan="1" style = "font-size:90%; color:black;" |FMC7 | ||
|colspan="1" style = "background:#006699;"| | |colspan="1" style = "background:#006699;"| | ||
|colspan="1" style = "font-size:80%;"|- | |colspan="1" style = "font-size:80%;"|- | ||
|colspan="1" style = "font-size:80%;"|FMC7 may be expressed in MZL and may be strong | |colspan="1" style = "font-size:80%;"|FMC7 may be expressed in MZL and may be strong | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" | | |colspan="1" style = "font-size:90%; color:black;" |CD5 | ||
|colspan="1" style = "background:#66e0ff;"| | |colspan="1" style = "background:#66e0ff;"| | ||
|colspan="1" style = "font-size:80%;"|- | |colspan="1" style = "font-size:80%;"|- | ||
|colspan="1" style = "font-size:80%;"|Expression of CD5 is uncommon in MZL | |colspan="1" style = "font-size:80%;"|Expression of CD5 is uncommon in MZL | ||
|- | |- | ||
|colspan="1" style = "font-size:90%;" | | |colspan="1" style = "font-size:90%;" |CD10 | ||
|colspan="1" style = "background:#66e0ff;"| | |colspan="1" style = "background:#66e0ff;"| | ||
|colspan="1" style = "font-size:80%;"|- | |colspan="1" style = "font-size:80%;"|- | ||
|colspan="1" style = "font-size:84%;"|Infrequently expressed, expression may suggest FL | |colspan="1" style = "font-size:84%;"|Infrequently expressed, expression may suggest FL | ||
|- | |- | ||
|colspan="1" style = "font-size:90%;" | | |colspan="1" style = "font-size:90%;" |CD11C | ||
|colspan="1" style = "background:#006699;"| | |colspan="1" style = "background:#006699;"| | ||
|colspan="1" style = "font-size:80%;"| | |colspan="1" style = "font-size:80%;"| | ||
|colspan="1" style = "font-size:84%;"|Frequently expressed in MZL and should be looked for | |colspan="1" style = "font-size:84%;"|Frequently expressed in MZL and should be looked for | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" | | |colspan="1" style = "font-size:90%; color:black;" |CD19 | ||
|colspan="1" style = "background:#004466;"| | |colspan="1" style = "background:#004466;"| | ||
|colspan="1" style = "font-size:80%;"|- | |colspan="1" style = "font-size:80%;"|- | ||
Revision as of 22:11, 4 July 2023
Typical MZL morphology, note the small/medium size, bland chromatin pattern in a slightly squared nucleus, and the tendency of cytoplasm to gently engage adjacent red cells
Background to flow cytometric diagnosis
A difficult diagnosis - flow cytometry can suggest a diagnosis, but the immunophenotype may overlap with related diagnoses including atypical cases of CLL and MCL. Generally it is correct to suggest the diagnosis, but recognise that the profile is not fully specific, and confirmation by other modalities may be required.
CD45 Expression
Side scatter
| Immunophenotype of MZL | |||
|---|---|---|---|
| Major markers useful in diagnosis | |||
| Marker | Freq | Level | Comment |
| κ/λ | Expect moderate or strong restricted κ or λ expression | ||
| FMC7 | - | FMC7 may be expressed in MZL and may be strong | |
| CD5 | - | Expression of CD5 is uncommon in MZL | |
| CD10 | - | Infrequently expressed, expression may suggest FL | |
| CD11C | Frequently expressed in MZL and should be looked for | ||
| CD19 | - | Expression is expected, typically more strongly than in CLL | |
| Other relevant markers | |||
| CD20 | - | Expression is expected, typically stronger than CLL | |
| CD23 | - | Typically not expressed by MZL, may rarely be expressed | |
| CD25 | May be expressed by MZL, not generally strong as HCL | ||
| CD38 | - | Expression is expected in MZL but CD138 should be absent | |
| CD43 | - | Lower expression than in CLL, may be helpful in some cases | |
| CD79b | Expression is expected and should be stronger than CLL | ||
| CD103 | - | Not expected in MZL, consider HCL if found | |
| CD138 | - | Expression may occur in MZL | |
| CD200 | - | Expression is obseved in MZL | |
Key to table:
Markers most useful in initial diagnosis are underlined in blue text
Key to colour code for expression frequency Click for link
Key to expression strength code and use Click for link